Covid19: comentarios [53638]

#16 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sun, 25 Sep 2022 09:25:49 +0000

#15 Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. www.ncbi.nlm.nih.gov/pubmed/34348657

Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. www.ncbi.nlm.nih.gov/pubmed/34351881

Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. www.ncbi.nlm.nih.gov/pubmed/33854395

Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. www.ncbi.nlm.nih.gov/pubmed/34446426

Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. www.ncbi.nlm.nih.gov/pubmed/34808708

Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. www.ncbi.nlm.nih.gov/pubmed/34347278

In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubme

Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. www.ncbi.nlm.nih.gov/pubmed/34463755

Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. www.ncbi.nlm.nih.gov/pubmed/34931681

Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. www.ncbi.nlm.nih.gov/pubmed/34342500

Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. www.ncbi.nlm.nih.gov/pubmed/34805376

Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. www.ncbi.nlm.nih.gov/pubmed/34834983

Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. www.ncbi.nlm.nih.gov/pubmed/34389692

Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. www.ncbi.nlm.nih.gov/pubmed/34270752

Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. www.ncbi.nlm.nih.gov/pubmed/34744118

Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. www.ncbi.nlm.nih.gov/pubmed/34568540

Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. www.ncbi.nlm.nih.gov/pubmed/34447639

Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. www.ncbi.nlm.nih.gov/pubmed/34185046

Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. www.ncbi.nlm.nih.gov/pubmed/34402228

King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. www.ncbi.nlm.nih.gov/pubmed/34396358

Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. www.ncbi.nlm.nih.gov/pubmed/34477808

Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. www.ncbi.nlm.nih.gov/pubmed/33898162

Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. www.ncbi.nlm.nih.gov/pubmed/33643776

Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. www.ncbi.nlm.nih.gov/pubmed/34952008

Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. www.ncbi.nlm.nih.gov/pubmed/34642628

Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. www.ncbi.nlm.nih.gov/pubmed/34540594

Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. www.ncbi.nlm.nih.gov/pubmed/34378087

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. www.ncbi.nlm.nih.gov/pubmed/34127854

Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. www.ncbi.nlm.nih.gov/pubmed/34393110

Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. www.ncbi.nlm.nih.gov/pubmed/34463770

Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. www.ncbi.nlm.nih.gov/pubmed/33606296

Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. www.ncbi.nlm.nih.gov/pubmed/34535317

Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. www.ncbi.nlm.nih.gov/pubmed/33888900

Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following...

» autor: function

#15 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sun, 25 Sep 2022 09:24:46 +0000

#14 Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. www.ncbi.nlm.nih.gov/pubmed/34617315

Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695

Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382

Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459

Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804

Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360

Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657

Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012

Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. www.ncbi.nlm.nih.gov/pubmed/34547487

Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. www.ncbi.nlm.nih.gov/pubmed/34339728

Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. www.ncbi.nlm.nih.gov/pubmed/34356586

Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. www.ncbi.nlm.nih.gov/pubmed/34219532

Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. www.ncbi.nlm.nih.gov/pubmed/34246585

Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. www.ncbi.nlm.nih.gov/pubmed/34492161

Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. www.ncbi.nlm.nih.gov/pubmed/34844930

Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. www.ncbi.nlm.nih.gov/pubmed/34487236

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. www.ncbi.nlm.nih.gov/pubmed/34551225

Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. www.ncbi.nlm.nih.gov/pubmed/34709227

Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. www.ncbi.nlm.nih.gov/pubmed/34921468

Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. www.ncbi.nlm.nih.gov/pubmed/34824230

Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. www.ncbi.nlm.nih.gov/pubmed/34170372

Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. www.ncbi.nlm.nih.gov/pubmed/34849667

Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. www.ncbi.nlm.nih.gov/pubmed/34646267

Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. www.ncbi.nlm.nih.gov/pubmed/34127481

Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. www.ncbi.nlm.nih.gov/pubmed/34538306

Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. www.ncbi.nlm.nih.gov/pubmed/34237049

Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. www.ncbi.nlm.nih.gov/pubmed/33406694

Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. www.ncbi.nlm.nih.gov/pubmed/34660088

Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. www.ncbi.nlm.nih.gov/pubmed/34916217

Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. www.ncbi.nlm.nih.gov/pubmed/34153517

Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. www.ncbi.nlm.nih.gov/pubmed/34668687

Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis...

» autor: function

#14 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sun, 25 Sep 2022 00:00:42 +0000

#13 COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/

Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.

Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.

COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.

Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/

Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/

Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.

New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.

Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/

ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/

Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.

Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/

Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.

Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/

COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.

Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.

Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/

Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/

A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/

Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/

Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/

Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/

Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/

A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/

Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/

COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/

Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.

Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.

COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.

Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/

Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/

Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.

New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.

Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/

ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/

Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.

Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/

Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.

Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/

COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.

Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.

Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. www.ncbi.nlm.nih.gov/pubmed/34416319

Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. www.ncbi.nlm.nih.gov/pubmed/34092429

Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. www.ncbi.nlm.nih.gov/pubmed/34025885

Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. www.ncbi.nlm.nih.gov/pubmed/34586408

Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. www.ncbi.nlm.nih.gov/pubmed/34756746

Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. www.ncbi.nlm.nih.gov/pubmed/34432976

Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. www.ncbi.nlm.nih.gov/pubmed/34754400

Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. www.ncbi.nlm.nih.gov/pubmed/34281357

Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. www.ncbi.nlm.nih.gov/pubmed/34835284

Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. www.ncbi.nlm.nih.gov/pubmed/34366403

Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. www.ncbi.nlm.nih.gov/pubmed/34564344

Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr...

» autor: function

#13 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 23:57:32 +0000

#12 Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: pubmed.ncbi.nlm.nih.gov/34807248/

Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34148772/

Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: pubmed.ncbi.nlm.nih.gov/34702550/

Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty ): pubmed.ncbi.nlm.nih.gov/33895650/

Deaths associated with recently launched SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34425384/

A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/

COVID-19 vaccine-induced urticarial vasculitis: pubmed.ncbi.nlm.nih.gov/34369046/.

ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34280507/.

New-onset leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34241833/

Cutaneous small vessel vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34529877/.

Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928638/

Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34836739/

Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; pubmed.ncbi.nlm.nih.gov/34495381/.

Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34327795

Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34660867/.

Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/

Reactivation of IgA vasculitis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34848431/

Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34310759/.

Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: pubmed.ncbi.nlm.nih.gov/34720009/

A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34518812/

Cutaneous vasculitis following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34611627/.

Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: pubmed.ncbi.nlm.nih.gov/34705320/.

IgA vasculitis following COVID-19 vaccination in an adult: pubmed.ncbi.nlm.nih.gov/34779011/

Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34451967/

Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: pubmed.ncbi.nlm.nih.gov/33928459/

Reactivation of IgA vasculitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34250509/

Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34292611/.

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: pubmed.ncbi.nlm.nih.gov/34530771/.

Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: pubmed.ncbi.nlm.nih.gov/34245294/.

Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34599716/.

Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: pubmed.ncbi.nlm.nih.gov/34115904/.

Henoch-Schönlein purpura occurring after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34247902/.

Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: pubmed.ncbi.nlm.nih.gov/34696186/.

Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34237323/.

Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34851795/.

A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34849386/

Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34310763/

Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34251683/.

Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: pubmed.ncbi.nlm.nih.gov/34557622/.

Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: pubmed.ncbi.nlm.nih.gov/34510694/

Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: pubmed.ncbi.nlm.nih.gov/34713472/803

Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34819272/

Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34337124/

Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: pubmed.ncbi.nlm.nih.gov/34535924/

Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: www.frontiersin.org/articles/10.3389/fmed.2021.798095/

COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: pubmed.ncbi.nlm.nih.gov/33591026/

Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: pubmed.ncbi.nlm.nih.gov/33625300/

Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: pubmed.ncbi.nlm.nih.gov/33774684/

Lymphadenopathy after COVID-19 vaccination: review of imaging findings: pubmed.ncbi.nlm.nih.gov/33985872/

Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34735411/

Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: pubmed.ncbi.nlm.nih.gov/34115709/.

COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: pubmed.ncbi.nlm.nih.gov/34257025/.

COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: pubmed.ncbi.nlm.nih.gov/34836672/.

Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: pubmed.ncbi.nlm.nih.gov/34280870/

COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: pubmed.ncbi.nlm.nih.gov/34432391/

Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: pubmed.ncbi.nlm.nih.gov/34731748/

Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: pubmed.ncbi.nlm.nih.gov/34906409/

Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/

Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/

A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/

Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/

Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/

Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/

Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/

A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/

Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/

COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other...

» autor: function

#12 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 23:55:59 +0000

#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/

Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/

A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.

A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.

Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/

Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.

Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.

Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.

Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/

Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/

SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/

Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/

Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.

Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/

Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.

Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/

Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34697502/

Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: pubmed.ncbi.nlm.nih.gov/33858693/

Acute transverse myelitis following inactivated COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34370410/

Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34579245/.

A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: pubmed.ncbi.nlm.nih.gov/34182207/

Post COVID-19 transverse myelitis; a case report with review of the literature: pubmed.ncbi.nlm.nih.gov/34457267/.

Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/

Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/

Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/

A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/

Acute pericarditis and cardiac tamponade after vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34749492/

Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34849667/

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34319393/

Acute myopericarditis after COVID-19 vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34589238/

Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34149145/

Case report: symptomatic pericarditis post COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34693198/.

An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: pubmed.ncbi.nlm.nih.gov/34797392/

Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): pubmed.ncbi.nlm.nih.gov/34862234/

Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: pubmed.ncbi.nlm.nih.gov/34396358/.

Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.

Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/

Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34591186/

Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34352309/

Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: pubmed.ncbi.nlm.nih.gov/34804803/.

Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: pubmed.ncbi.nlm.nih.gov/34077572/

Retinal hemorrhage after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34884407/.

Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/

Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34783899/

Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34549178/.

Brain death in a vaccinated patient with COVID-19 infection: pubmed.ncbi.nlm.nih.gov/34656887/

Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34236717/.

Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.

A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33932458/

Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: pubmed.ncbi.nlm.nih.gov/34092400/742.

Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34754937/

Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/

Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34846583/

COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/

Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/

Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: www.medrxiv.org/content/10.1101/2021.12.02.21267156v1

Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: pubmed.ncbi.nlm.nih.gov/33851711/

Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: pubmed.ncbi.nlm.nih.gov/34675550/.

Anaphylaxis after Modern COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34734159/.

Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34698847/

Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: pubmed.ncbi.nlm.nih.gov/34020815/

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/

Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/

Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/

Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/

Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/

Acute myocardial infarction and myocarditis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34586408/

Takotsubo syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34539938/.

Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: pubmed.ncbi.nlm.nih.gov/34731486/.

Premature myocardial infarction or side effect of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33824804/

Myocardial infarction, stroke, and pulmonary embolism...

» autor: function

#11 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 17:23:46 +0000

#10 Perimyocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34866957/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: pubmed.ncbi.nlm.nih.gov/34849657/.

Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/

Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: pubmed.ncbi.nlm.nih.gov/34605853/

Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/

Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34744118/

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: pubmed.ncbi.nlm.nih.gov/34334935/.

Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/

Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.

Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/

Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: pubmed.ncbi.nlm.nih.gov/34185045/

Myocarditis after BNT162b2 vaccination in a healthy male: pubmed.ncbi.nlm.nih.gov/34229940/

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/

Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34308326/.

Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/

Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/

Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/

Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/

Acute myocarditis in a young adult two days after vaccination with Pfizer: pubmed.ncbi.nlm.nih.gov/34709227/

Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/

Acute myocarditis after 2019 coronavirus disease vaccination: pubmed.ncbi.nlm.nih.gov/34734821/

A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: pubmed.ncbi.nlm.nih.gov/34246585/

Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34228985/

Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34852213/

Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: pubmed.ncbi.nlm.nih.gov/34866122/

Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: pubmed.ncbi.nlm.nih.gov/34601566/

Myocarditis following COVID-19 vaccination: MRI study: pubmed.ncbi.nlm.nih.gov/34739045/.

Acute myocarditis after COVID-19 vaccination: case report: docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e

Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: pubmed.ncbi.nlm.nih.gov/34374740/

Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: pubmed.ncbi.nlm.nih.gov/34865500/

Myocarditis following vaccination with Covid-19 in a large healthcare organization: pubmed.ncbi.nlm.nih.gov/34614329/

AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: pubmed.ncbi.nlm.nih.gov/34560365/

COVID-19, Guillain-Barré and vaccineA dangerous mix: pubmed.ncbi.nlm.nih.gov/34108736/.

Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.

Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: link.springer.com/article/10.1007/s10072-021-05523-5.

COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: onlinelibrary.wiley.com/doi/10.1002/ana.26258.

Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: jamanetwork.com/journals/jama/fullarticle/2785009

A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34567447/

Guillain-Barré syndrome associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34648420/.

Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2783708

Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.

Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34114256/.

Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34767184/.

Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: pubmed.ncbi.nlm.nih.gov/34644738/.

Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: pubmed.ncbi.nlm.nih.gov/34649856/

A rare case of Guillain-Barré syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34671572/

Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33758714/

COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: pubmed.ncbi.nlm.nih.gov/34484780/

Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; pubmed.ncbi.nlm.nih.gov/34779385/.

Miller Fisher syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34817727/.

Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: pubmed.ncbi.nlm.nih.gov/34789193/.

Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261746/

Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: pubmed.ncbi.nlm.nih.gov/34217513/.

» autor: function

#10 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 17:22:43 +0000

#9 Hypersensitivity Myocarditis and COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34856634/.

Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7.

Acute myocardial infarction and myocarditis after COVID-19 vaccination: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/

Myocarditis after Covid-19 vaccination in a large healthcare organization: www.nejm.org/doi/10.1056/NEJMoa2110737

Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052

Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=

STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. pubmed.ncbi.nlm.nih.gov/34756746/

Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/

Myocarditis after COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34546329/.

Patients with acute myocarditis after COVID-19 mRNA vaccination:. jamanetwork.com/journals/jamacardiology/fullarticle/2781602.

Myocarditis after COVID-19 vaccination: a case series: www.sciencedirect.com/science/article/pii/S0264410X21011725?via=ihub.

Myocarditis associated with COVID-19 vaccination in adolescents: publications.aap.org/pediatrics/article/148/5/e2021053427/181357

Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. pubmed.ncbi.nlm.nih.gov/34704459/

Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230.

Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/

Myocarditis after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S2352906721001603

Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administ.

Myocarditis associated with COVID-19 mRNA vaccination: pubs.rsna.org/doi/10.1148/radiol.2021211430

Acute myocarditis after COVID-19 vaccination: a case report: www.sciencedirect.com/science/article/pii/S0248866321007098

Acute myopericarditis after COVID-19 vaccination in adolescents:. pubmed.ncbi.nlm.nih.gov/34589238/.

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: academic.oup.com/jpids/article/10/10/962/6329543.

Acute myocarditis associated with anti-COVID-19 vaccination: ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.

Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. pubmed.ncbi.nlm.nih.gov/34428917/.

Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. pubmed.ncbi.nlm.nih.gov/34088762/.

Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6.

COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: www.mdpi.com/2036-7503/13/3/61.

Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34402228/

Myocarditis temporally associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34133885/

Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/

Acute myocarditis associated with COVID-19 vaccination: report of a case: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/

Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: pubmed.ncbi.nlm.nih.gov/34840235/.

Myocarditis in the setting of a recent COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34712497/.

Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.

Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/

Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.

Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/

Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/

Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34615534/

Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34352418/

Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.

CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/

Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: haematologica.org/article/view/haematol.2021.279075

COVID-19 vaccine-induced thrombosis: pubmed.ncbi.nlm.nih.gov/34802488/.

Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.

Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34863404/.

Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: www.sciencedirect.com/science/article/pii/S235255682100093X

Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34876440/

Deep venous thrombosis more than two weeks after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33928773/

Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/

Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34587242/

Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/

Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/

Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.

Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258

Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: pubmed.ncbi.nlm.nih.gov/34579636/

Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/

Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/

Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): pubmed.ncbi.nlm.nih.gov/33624509/.

Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/

Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/

Myocarditis associated with COVID-19 vaccination in three adolescent boys: pubmed.ncbi.nlm.nih.gov/34851078/.

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/

Perimyocarditis...

» autor: function

#9 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 17:20:39 +0000

#8 Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34546343/

Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/

Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.

A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.

Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/

Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.

Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.

Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/

Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/

Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.

Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/

Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/

Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/

Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138

Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.

Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.

Relapse of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34591991/

Thrombosis in pre- and post-vaccination phase of COVID-19; pubmed.ncbi.nlm.nih.gov/34650382/

A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/

COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: pubmed.ncbi.nlm.nih.gov/34786893/

Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/

Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/

An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34790811/

Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.

Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: pubmed.ncbi.nlm.nih.gov/34629931/

Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/

Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/

Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/

Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/

Autoimmune roots of thrombotic events after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34508917/.

New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.

Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33962903/.

Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: pubmed.ncbi.nlm.nih.gov/34796065/.

Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/

A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/

Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): pubmed.ncbi.nlm.nih.gov/34595867/

A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): pubmed.ncbi.nlm.nih.gov/34820240/

Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: pubmed.ncbi.nlm.nih.gov/33851389/

Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: pubmed.ncbi.nlm.nih.gov/33980419/

Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34264151/

Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: pubmed.ncbi.nlm.nih.gov/34734086/

Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: pubmed.ncbi.nlm.nih.gov/34755555/

Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/

Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34264514/.

Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34840204/

Neurological side effects of SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34750810/

Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/

Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/

Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: pubmed.ncbi.nlm.nih.gov/34571653/.

Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: pubmed.ncbi.nlm.nih.gov/34835275/.

Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: pubmed.ncbi.nlm.nih.gov/34659839/.

Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34668274/.

Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34549821/

Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): pubmed.ncbi.nlm.nih.gov/34528522/

Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/.

Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408

Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/

Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/

Myocarditis Following mRNA COVID-19 Vaccine: journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.

Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: pubmed.ncbi.nlm.nih.gov/34614328/.

Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext

Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: pubmed.ncbi.nlm.nih.gov/34246586/

Hypersensitivity Myocarditis and...

» autor: function

#8 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 13:03:27 +0000

#7 Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34620638/

Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: pubmed.ncbi.nlm.nih.gov/34650896/

Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34625447/

Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/

Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34548920/

Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): pubmed.ncbi.nlm.nih.gov/34672380/.

Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: pubmed.ncbi.nlm.nih.gov/34556531/.

Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: pubmed.ncbi.nlm.nih.gov/34535076/.

Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: pubmed.ncbi.nlm.nih.gov/34379914/.

Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/

Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/

In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/

Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/

Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/

Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: pubmed.ncbi.nlm.nih.gov/34695859/

Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: pubmed.ncbi.nlm.nih.gov/34453762/.

Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: pubmed.ncbi.nlm.nih.gov/34660652/.

Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/

Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: pubmed.ncbi.nlm.nih.gov/34694650/

Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/

Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/

Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.

Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34839563/

Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34783932/.

COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/

Inflammatory myositis after vaccination with ChAdOx1: pubmed.ncbi.nlm.nih.gov/34585145/

Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.

A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/

COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: pubmed.ncbi.nlm.nih.gov/34527501/

Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/

Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/

Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2784622

Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781321/

Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34062319/

Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/

COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.

Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34751013/.

Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34684047/.

Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34541935/

Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34273119/

Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.

Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/

Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/

Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.

Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34609603/

Case report: Pityriasis rosea-like rash after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34557507/

Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34641797/.

Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: pubmed.ncbi.nlm.nih.gov/34812326/.

Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/

Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.

Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.

Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/

Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.

Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: pubmed.ncbi.nlm.nih.gov/34590397/

Sudden sensorineural hearing loss after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34670143/.

Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.

Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34581453/

Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: pubmed.ncbi.nlm.nih.gov/34741583/

Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34631069/

Thrombosis after COVID-19 vaccination: possible link to ACE pathways: pubmed.ncbi.nlm.nih.gov/34479129/

Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/

Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): pubmed.ncbi.nlm.nih.gov/34546608/

Abdominal pain and bilateral...

» autor: function

#7 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 13:02:19 +0000

#6 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: pubmed.ncbi.nlm.nih.gov/33929487/.

Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/

Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/

Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.

Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/

Autoimmunity roots of thrombotic events after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34508917/

Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/

Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/

Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/

An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/

Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/

Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/

First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/

ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.

Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/

Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/

Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: pubmed.ncbi.nlm.nih.gov/34273119/

Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/

A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/

Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.

Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.

Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.

Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.

Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.

Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34384129/

Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34261296/

Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: pubmed.ncbi.nlm.nih.gov/34250318/.

A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: pubmed.ncbi.nlm.nih.gov/34059191/

Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/

Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/

Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/

Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.

Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: onlinelibrary.wiley.com/doi/10.1111/trf.16672

Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI

A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/

This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475

Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: www.sciencedirect.com/science/article/pii/S1201971221007797

Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.

Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: www.sciencedirect.com/science/article/pii/S0168827821020936

Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: www.nature.com/articles/s41421-021-00329-3

Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/

Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:www.science.org/doi/10.1126/sciadv.abl8213

Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/

A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469Â435.

VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34731555/

Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/

Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/

Spectrum of neurological complications after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34719776/.

Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/

Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/

Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/

Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...

» autor: function

#6 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 11:50:18 +0000

#5 Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34462647/

Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34325334/

Tolosa-Hunt syndrome occurring after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34513398/

Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.

Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34077949/

Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34171435/

Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34447349/

Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34514078/

Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34406660/.

IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34509658/

A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34196469/.

Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/

Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34436620/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.

Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/

Immune thrombocytopenia after vaccination during the COVID-19 pandemic: pubmed.ncbi.nlm.nih.gov/34435486/

COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/

Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34429981/

Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: pubmed.ncbi.nlm.nih.gov/34427024/

Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34510014/.

Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/

Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/

Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34515024/

Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/.

Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34363637/

Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: www.sciencedirect.com/science/article/pii/S2214250921002018

Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: casereports.bmj.com/content/14/5/e242220.abstract.

Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34155844/

Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.

Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.

Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.

Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: casereports.bmj.com/content/14/7/e242678.

Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-

Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines

Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/.

Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: pubmed.ncbi.nlm.nih.gov/34327553/.

Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33878469/.

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.

Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34090750/.

Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34312301/.

Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34333995/

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/

Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34111775/.

Cerebral venous thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/

Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/

Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/

Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.

Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/

Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/

Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/

Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: pubmed.ncbi.nlm.nih.gov/33845870/.

Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/.

Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.

Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.

Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/

Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/

Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/

A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/

Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/

U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...

» autor: function

#5 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 11:49:18 +0000

#4 Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/

celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: pubmed.ncbi.nlm.nih.gov/34261633/.

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34256983/

Thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34332437/.

Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33845870/.

Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: pubmed.ncbi.nlm.nih.gov/34236343/

Acute myocardial infarction within 24 hours after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34364657/.

Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34287612/

central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/

Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/

Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/

A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34137813/

Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34191218/

Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/

New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34153802/

Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: pubmed.ncbi.nlm.nih.gov/34092488/

Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/

Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/.

Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34144250/

Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/33687691/

Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34011137/.

Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/.

Atypical thrombosis associated with the vaccine VaxZevria (AstraZeneca): data from the French network of regional pharmacovigilance centers: pubmed.ncbi.nlm.nih.gov/34083026/.

Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.

Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: pubmed.ncbi.nlm.nih.gov/34235757/.

Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34473841/.

Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/

Cerebral venous thrombosis following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/.

Lipschütz ulcers after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34366434/.

Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: pubmed.ncbi.nlm.nih.gov/34330677/

Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: pubmed.ncbi.nlm.nih.gov/34181446/

Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34477089/

Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: pubmed.ncbi.nlm.nih.gov/34071883/

Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34033367/

Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: pubmed.ncbi.nlm.nih.gov/34375510/

Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34107198/

Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34355379/.

A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: pubmed.ncbi.nlm.nih.gov/34452028/

Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/

Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.

Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34105247/.

Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34405870/.

Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34416410/.

Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34462013/.

Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34224024/.

Post-vaccinal encephalitis after ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34324214/

Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: pubmed.ncbi.nlm.nih.gov/34507266/

Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: pubmed.ncbi.nlm.nih.gov/34459725/

Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/

Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: pubmed.ncbi.nlm.nih.gov/34043800/.

Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: pubmed.ncbi.nlm.nih.gov/34447646/

Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.

fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: pubmed.ncbi.nlm.nih.gov/34416319/.

Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/

Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34291477/

Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34513435/

Hepatitis C virus reactivation after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34512037/

Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: pubmed.ncbi.nlm.nih.gov/34483273/.

Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: pubmed.ncbi.nlm.nih.gov/34513446/

Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: pubmed.ncbi.nlm.nih.gov/34474550/

Reactive arthritis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34033732/.

Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: pubmed.ncbi.nlm.nih.gov/33858208/

Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: pubmed.ncbi.nlm.nih.gov/34015240/

Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34482558/

COVID-19 mRNA vaccine causing CNS inflammation: a case series: pubmed.ncbi.nlm.nih.gov/34480607/

Thymic

» autor: function

#4 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Sat, 24 Sep 2022 11:48:05 +0000

#3 Allergic reactions after COVID-19 vaccination: putting the risk in perspective: pubmed.ncbi.nlm.nih.gov/34463751/

Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: pubmed.ncbi.nlm.nih.gov/33846043/ 188.

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: pubmed.ncbi.nlm.nih.gov/33752263/

COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/

Fatal brain hemorrhage after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928772/

A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: pubmed.ncbi.nlm.nih.gov/34423106/

Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: pubmed.ncbi.nlm.nih.gov/33838206/

Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: pubmed.ncbi.nlm.nih.gov/34517079/

Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: pubmed.ncbi.nlm.nih.gov/34254291/

Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: pubmed.ncbi.nlm.nih.gov/34487581/

Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: pubmed.ncbi.nlm.nih.gov/33987882/

Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34138513/

Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: pubmed.ncbi.nlm.nih.gov/34365148/.

Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: pubmed.ncbi.nlm.nih.gov/34452064/.

A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33917902/

Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): pubmed.ncbi.nlm.nih.gov/34256983/

Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34247246/.

Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34132839/

59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34117206/

Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: pubmed.ncbi.nlm.nih.gov/34033927/

Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/

Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34364831/

Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: pubmed.ncbi.nlm.nih.gov/34447639/

Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: pubmed.ncbi.nlm.nih.gov/34514306/

Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/

Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: pubmed.ncbi.nlm.nih.gov/34453510/

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: pubmed.ncbi.nlm.nih.gov/33476455/

propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34451967/

Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34377889/

Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/

COVID-19 vaccination association and facial nerve palsy: A case-control study: pubmed.ncbi.nlm.nih.gov/34165512/

The association between COVID-19 vaccination and Bell’s palsy: pubmed.ncbi.nlm.nih.gov/34411533/

Bell’s palsy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33611630/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): pubmed.ncbi.nlm.nih.gov/33981305/

Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: pubmed.ncbi.nlm.nih.gov/34336436/

Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34281950/.

Transverse myelitis induced by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34458035/

Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): pubmed.ncbi.nlm.nih.gov/33734623/

Acute abducens nerve palsy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34044114/.

Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: pubmed.ncbi.nlm.nih.gov/34492394/

Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34369471/

Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34014316/

Bell’s palsy after COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34330676/

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34272622/

Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: pubmed.ncbi.nlm.nih.gov/34477091/

Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33975372/.

Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: pubmed.ncbi.nlm.nih.gov/34322761/.

Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: pubmed.ncbi.nlm.nih.gov/34139321/.

Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: pubmed.ncbi.nlm.nih.gov/34032902/.

Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: pubmed.ncbi.nlm.nih.gov/33862041/

Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34332438/

Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: pubmed.ncbi.nlm.nih.gov/34293683/.

Autoimmune hepatitis after COVID vaccine: pubmed.ncbi.nlm.nih.gov/34225251/

A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: pubmed.ncbi.nlm.nih.gov/34449715/

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: pubmed.ncbi.nlm.nih.gov/34139631/.

Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/33864750/

Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33914590/

Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34420802/

Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/

Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34174723/

Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/

First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/

Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/

Malignant cerebral infarction after...

» autor: function

#3 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Fri, 23 Sep 2022 23:13:15 +0000

#2 Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: pubmed.ncbi.nlm.nih.gov/34236331/

Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/

COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: pubmed.ncbi.nlm.nih.gov/34186348/.

GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: www.sciencedirect.com/science/article/pii/S2666354621000065

Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: www.sciencedirect.com/science/article/pii/S0303846721004169

Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: www.sciencedirect.com/science/article/pii/S0165572821002186

Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: www.sciencedirect.com/science/article/pii/S2214250921000998.

Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: www.sciencedirect.com/science/article/pii/S0736467921006442

Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: www.sciencedirect.com/science/article/pii/S0035378721005853.

SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: www.sciencedirect.com/science/article/pii/S2049080121005343

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: www.sciencedirect.com/science/article/pii/S2049080121007536

Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: www.sciencedirect.com/science/article/pii/S1201971221007049

Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: www.sciencedirect.com/science/article/pii/S0899707121003557.

New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: www.sciencedirect.com/science/article/pii/S0165572821001569

Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: www.sciencedirect.com/science/article/pii/S0165572821002137

Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: www.sciencedirect.com/science/article/pii/S1473309921002735

Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: www.sciencedirect.com/science/article/pii/S266635462100020X

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. www.sciencedirect.com/science/article/pii/S2451993621001456.

Bell’s palsy after COVID-19 vaccination: case report: www.sciencedirect.com/science/article/pii/S217358082100122X.

An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: www.sciencedirect.com/science/article/pii/S2213219821007972

COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: www.sciencedirect.com/science/article/pii/S1930043321002612

ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: www.sciencedirect.com/science/article/pii/S0272638621007423

Late cutaneous reactions after administration of COVID-19 mRNA vaccines: www.sciencedirect.com/science/article/pii/S2213219821007996

COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: www.sciencedirect.com/science/article/pii/S1871402121001880

Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: www.sciencedirect.com/science/article/pii/S0190962221024427

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. www.sciencedirect.com/science/article/abs/pii/S0735675721004381.

COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. www.sciencedirect.com/science/article/pii/S1939455121000119.

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. www.sciencedirect.com/science/article/pii/S1871402121002046.

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. www.sciencedirect.com/science/article/abs/pii/S188558572100133X

Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. www.sciencedirect.com/science/article/pii/S0896841121000937.

immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. www.sciencedirect.com/science/article/pii/S2214250921002018.

Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: www.sciencedirect.com/science/article/pii/S1876034121001878.

COVID-19 RNA-based vaccines and the risk of prion disease: scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion- ease-1503.pdf

This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: www.nejm.org/doi/full/10.1056/NEJMoa2104983.

Process-related impurities in the ChAdOx1 nCov-19 vaccine: www.researchsquare.com/article/rs-477964/v1

COVID-19 mRNA vaccine causing CNS inflammation: a case series: link.springer.com/article/10.1007/s00415-021-10780-7

Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33475702/

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: pubmed.ncbi.nlm.nih.gov/33320974/

Pfizer Vaccine Raises Allergy Concerns: pubmed.ncbi.nlm.nih.gov/33384356/

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: pubmed.ncbi.nlm.nih.gov/33444297/

Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: pubmed.ncbi.nlm.nih.gov/33507892/

Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: pubmed.ncbi.nlm.nih.gov/34414880/

Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: pubmed.ncbi.nlm.nih.gov/33576785/

Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: pubmed.ncbi.nlm.nih.gov/34269740/

Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34215453/

Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: pubmed.ncbi.nlm.nih.gov/33932618/

Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): pubmed.ncbi.nlm.nih.gov/33643776/

Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/33571463/

Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: pubmed.ncbi.nlm.nih.gov/33527524/

Cutaneous adverse effects of available COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34518015/

Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: pubmed.ncbi.nlm.nih.gov/34347278/

COVID-19 vaccines increase the risk of anaphylaxis: pubmed.ncbi.nlm.nih.gov/33685103/

Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: pubmed.ncbi.nlm.nih.gov/33657648/

Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33825239/

Acute allergic reactions to COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/33683290/

Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: pubmed.ncbi.nlm.nih.gov/33919151/

Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: pubmed.ncbi.nlm.nih.gov/34128049/

Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: pubmed.ncbi.nlm.nih.gov/34474708/

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447

.IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34318537/

Allergic reactions after COVID-19 vaccination: putting the risk in perspective...

» autor: function

#2 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Fri, 23 Sep 2022 23:11:40 +0000

#1 Exacerbation of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34075578/

First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34105244/

PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: www.nejm.org/doi/full/10.1056/NEJMc2106383

Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: www.nature.com/articles/s41586-021-03744-4

Myocarditis with COVID-19 mRNA vaccines: www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135

Myocarditis and pericarditis after COVID-19 vaccination: jamanetwork.com/journals/jama/fullarticle/2782900

Myocarditis temporally associated with COVID-19 vaccination: www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.

COVID-19 Vaccination Associated with Myocarditis in Adolescents: pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/ped

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: pubmed.ncbi.nlm.nih.gov/33994339/

Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: www.sciencedirect.com/science/article/pii/S1553838921005789

COVID-19 vaccine-induced myocarditis: a case report with review of the literature: www.sciencedirect.com/science/article/pii/S1871402121002253

Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: www.sciencedirect.com/science/article/pii/S1936878X2100485X

Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: www.sciencedirect.com/science/article/pii/S002234762100617X

Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: www.sciencedirect.com/science/article/pii/S0167527321012286.

Acute myocarditis after administration of BNT162b2 vaccine: www.sciencedirect.com/science/article/pii/S2214250921001530

Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: www.sciencedirect.com/science/article/pii/S2352906721001573

Myocarditis following vaccination with BNT162b2 in a healthy male: www.sciencedirect.com/science/article/pii/S0735675721005362

Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: www.sciencedirect.com/science/article/pii/S1930043321005549

Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: www.sciencedirect.com/science/article/pii/S002234762100665X

Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: www.sciencedirect.com/science/article/pii/S1885585721002218

Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: www.sciencedirect.com/science/article/pii/S2589790X21001931

Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: www.sciencedirect.com/science/article/pii/S2352906721000622

Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: www.sciencedirect.com/science/article/pii/S0022347621007368

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: www.sciencedirect.com/science/article/pii/S0870255121003243

Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: www.sciencedirect.com/science/article/pii/S0022347621007496

A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: www.sciencedirect.com/science/article/pii/S1936878X21004861

Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: www.sciencedirect.com/science/article/pii/S1443950621011331

COVID-19 mRNA vaccination and myocarditis: pubmed.ncbi.nlm.nih.gov/34268277/

COVID-19 vaccine and myocarditis: pubmed.ncbi.nlm.nih.gov/34399967/

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/re en/covidwho-1360706.

COVID-19 vaccines and myocarditis: pubmed.ncbi.nlm.nih.gov/34246566/

Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-com lications-of-the-mrna-based-covid-19-vaccines www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-com

Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34340927/

Myocarditis with covid-19 mRNA vaccines: www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135

Association of myocarditis with COVID-19 mRNA vaccine in children: media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-c vid-19-vaccine-in-children/

Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052

Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: jamanetwork.com/journals/jamacardiology/fullarticle/2781601\

Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: jamanetwork.com/journals/jamacardiology/fullarticle/2781600

Myocarditis following immunization with Covid-19 mRNA: www.nejm.org/doi/full/10.1056/NEJMc2109975

Patients with acute myocarditis after vaccination withCOVID-19 mRNA: jamanetwork.com/journals/jamacardiology/fullarticle/2781602

Myocarditis associated with vaccination with COVID-19 mRNA: pubs.rsna.org/doi/10.1148/radiol.2021211430

Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: pediatrics.aappublications.org/content/148/3/e2021052478

Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4

Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myoc

Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34402228/

Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: academic.oup.com/ehjcr/article/5/8/ytab319/6339567

Myocarditis / pericarditis associated with COVID-19 vaccine: science.gc.ca/eic/site/063.nsf/eng/h_98291.html

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adoles nts_Receiving.95800.aspx

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/63295

The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: pubmed.ncbi.nlm.nih.gov/34312010/

Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: pubmed.ncbi.nlm.nih.gov/34219532/

Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033

Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236

In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038

Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: pubmed.ncbi.nlm.nih.gov/34333695/

Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/

Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: pubmed.ncbi.nlm.nih.gov/34118375/

Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/

Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/

Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059

Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: pubmed.ncbi.nlm.nih.gov/34447639/

Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-0218

Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipit

» autor: function

#1 Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

function — Fri, 23 Sep 2022 23:04:57 +0000

Where is the evidence?

Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/

Fatal cerebral hemorrhage after COVID-19 vaccine:

pubmed.ncbi.nlm.nih.gov/33928772/

Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: www.sciencedirect.com/science/article/pii/S2666602221000409

Three cases of acute venous thromboembolism in women after vaccination against COVID-19: www.sciencedirect.com/science/article/pii/S2213333X21003929

Acute thrombosis of the coronary tree after vaccination against COVID-19: www.sciencedirect.com/science/article/abs/pii/S1936879821003988

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: pubmed.ncbi.nlm.nih.gov/33929487/

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/

Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): pubmed.ncbi.nlm.nih.gov/33871350/

Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: www.sciencedirect.com/science/article/pii/S0022510X21003014

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: www.sciencedirect.com/science/article/abs/pii/S0735675721004381

Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: www.sciencedirect.com/science/article/abs/pii/S0033062021000505

Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: www.sciencedirect.com/science/article/abs/pii/S0953620521001904

COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: www.sciencedirect.com/science/article/pii/S1665268121000557

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): www.sciencedirect.com/science/article/pii/S1050173821000967

Roots of autoimmunity of thrombotic events after COVID-19 vaccination: www.sciencedirect.com/science/article/abs/pii/S1568997221002160

Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/ful

Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: www.nejm.org/doi/full/10.1056/nejme2106315

Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: jamanetwork.com/journals/jamacardiology/fullarticle/2781601

Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelate

Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: pubmed.ncbi.nlm.nih.gov/34374740/

Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelate

Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): haematologica.org/article/view/haematol.2021.279075

Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): www.sciencedirect.com/science/article/pii/S0264410X21005247

Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-0524

Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005

Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: www.sciencedirect.com/science/article/abs/pii/S0896841121000895

Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: www.sciencedirect.com/science/article/abs/pii/S0049384821003315

Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: www.sciencedirect.com/science/article/pii/S0896841121000937

Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: www.sciencedirect.com/science/article/abs/pii/S1052305721003098

Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): www.sciencedirect.com/science/article/pii/S0953620521002363

Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: www.sciencedirect.com/science/article/pii/S0828282X21006243

“Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: www.sciencedirect.com/science/article/pii/S2666572721000389

Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: www.sciencedirect.com/science/article/pii/S0196064421003425

Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S1443950621011562

Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: www.sciencedirect.com/science/article/abs/pii/S0896841121000706

Prothrombotic immune thrombocytopenia after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S0006497121009411

Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: www.sciencedirect.com/science/article/pii/S2589936821000256

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: www.sciencedirect.com/science/article/pii/S1871402121002046

Thrombosis after COVID-19 vaccination: possible link to ACE pathways: www.sciencedirect.com/science/article/pii/S0049384821004369

Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: www.sciencedirect.com/science/article/pii/S0735109721051949

A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S0735675721005714

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: www.sciencedirect.com/science/article/abs/pii/S088915912100163X

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): www.sciencedirect.com/science/article/abs/pii/S0006497121013963.

Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ

Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: www.sciencedirect.com/science/article/pii/S0953620521002314

Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S0213485321000839

Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: pubmed.ncbi.nlm.nih.gov/33918932/

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33606296/

Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33854395/

Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/

COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: pubmed.ncbi.nlm.nih.gov/33863748/

Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: onlinelibrary.wiley.com/doi/10.1002/ana.26172

Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: pubmed.ncbi.nlm.nih.gov/34133027/

The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34001390/

Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: pubmed.ncbi.nlm.nih.gov/34181446/

Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34174723/

First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: www.nature.com/articles/s41591-021-01408-4

Exacerbation of immune...

» autor: function